ABSTRACT Periodontitis, a chronic inflammatory condition triggered by microbial dysbiosis and host immunological responses, is increasingly being addressed using phytoextracted formulations that incorporate plant‐derived bioactive substances. These formulations, which include gels, mouthwashes, and polyherbal combinations, have antibacterial, anti‐inflammatory, and antioxidant characteristics that target important pathogenic pathways such as biofilm formation, cytokine release, and oxidative stress. Active ingredients such as gingerol, tannins, and rosmarinic acid inhibit matrix metalloproteinases, reduce pro‐inflammatory cytokines, and neutralize free radicals, reducing tissue breakdown. Phytoextracted formulations incorporate multiple plant‐derived extracts, such as tea tree oil, neem, and clove, to enhance antibacterial efficacy against red‐complex infections like Porphyromonas gingivalis, Treponema denticola, and Bacteroides forsythus . Despite encouraging in vitro and animal research, clinical adoption confronts several hurdles, including poor plant extract standardization, varying dosage regimens, and a lack of long‐term human trials. Chamomile ( Matricaria recutita ) mouthwashes demonstrated a 30% reduction in bleeding indices compared to chlorhexidine in clinical trials, suggesting comparable efficacy. Future efforts should also address industry adoption, regulatory approvals, and large‐scale manufacturing challenges to integrate phytoextracted formulations into mainstream oral healthcare products effectively.
Kumar et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: